Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
P/E ratio for Terns Pharmaceuticals, Inc. (TERN)
P/E ratio as of 2023: -5.13
According to Terns Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.13. At the end of 2022 the company had a P/E ratio of -6.08.
P/E ratio history for Terns Pharmaceuticals, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -5.13 |
| 2022 | -6.08 |
| 2021 | -3.56 |
| 2020 | -11.39 |
| 2019 | -6.71 |
| 2018 | -24.89 |